Divergent effects of age on imaging-based ATN biomarkers and cognition in Alzheimer's disease.

IF 4.4 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2025-08-11 eCollection Date: 2025-07-01 DOI:10.1002/dad2.70142

Lars Frings, Sabine Hellwig, Joachim Brumberg, Alexander Rau, Michael Mix, Ganna Blazhenets, Horst Urbach, Philipp T Meyer

{"title":"Divergent effects of age on imaging-based ATN biomarkers and cognition in Alzheimer's disease.","authors":"Lars Frings, Sabine Hellwig, Joachim Brumberg, Alexander Rau, Michael Mix, Ganna Blazhenets, Horst Urbach, Philipp T Meyer","doi":"10.1002/dad2.70142","DOIUrl":null,"url":null,"abstract":"Introduction: We investigated whether age of patients with Alzheimer's disease (AD) at first visit to a memory clinic predicts biomarker findings along the amyloid beta deposition, pathologic tau, and neurodegeneration (ATN) scheme and moderates the association between ATN biomarkers and cognition.Methods: We evaluated [11C]Pittsburgh compound B positron emission tomography (PET), florzolotau (18F) PET, [18F]fluorodeoxyglucose PET, T1-weighted magnetic resonance imaging, and cognitive assessments (N = 190/63/252/687/2198) of a total of 2355 AD patients. We assessed direct and moderating effects of age.Results: Tau burden and hypometabolism were more severe in younger AD patients. Gray matter volume of the medial temporal lobe (MTL) was reduced to a greater extent in older patients. Relationships between different imaging modalities or between single imaging modalities and cognition were not moderated by age.Discussion: In contrast to more severe tau burden and hypometabolism in younger patients, MTL atrophy was more pronounced in older patients. Relationships between markers of pathology and those of neurodegeneration were not associated with age.Highlights: Amyloid beta load as a biomarker of pathology burden was not associated with age at first visit to a memory clinic.Tau burden was higher, and glucose metabolism was lower in younger Alzheimer's disease (AD) patients.By contrast, medial temporal lobe atrophy was less severe in younger AD patients.Younger AD patients showed more severe memory deficits with respect to age-appropriate normative data.Age had no moderating effect on relationships between different imaging variables or between single imaging variables and cognition.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70142"},"PeriodicalIF":4.4000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337748/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70142","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: We investigated whether age of patients with Alzheimer's disease (AD) at first visit to a memory clinic predicts biomarker findings along the amyloid beta deposition, pathologic tau, and neurodegeneration (ATN) scheme and moderates the association between ATN biomarkers and cognition.

Methods: We evaluated [¹¹C]Pittsburgh compound B positron emission tomography (PET), florzolotau (¹⁸F) PET, [¹⁸F]fluorodeoxyglucose PET, T1-weighted magnetic resonance imaging, and cognitive assessments (N = 190/63/252/687/2198) of a total of 2355 AD patients. We assessed direct and moderating effects of age.

Results: Tau burden and hypometabolism were more severe in younger AD patients. Gray matter volume of the medial temporal lobe (MTL) was reduced to a greater extent in older patients. Relationships between different imaging modalities or between single imaging modalities and cognition were not moderated by age.

Discussion: In contrast to more severe tau burden and hypometabolism in younger patients, MTL atrophy was more pronounced in older patients. Relationships between markers of pathology and those of neurodegeneration were not associated with age.

Highlights: Amyloid beta load as a biomarker of pathology burden was not associated with age at first visit to a memory clinic.Tau burden was higher, and glucose metabolism was lower in younger Alzheimer's disease (AD) patients.By contrast, medial temporal lobe atrophy was less severe in younger AD patients.Younger AD patients showed more severe memory deficits with respect to age-appropriate normative data.Age had no moderating effect on relationships between different imaging variables or between single imaging variables and cognition.

查看原文本刊更多论文

年龄对阿尔茨海默病基于成像的ATN生物标志物和认知的不同影响

简介：我们研究了首次访问记忆诊所的阿尔茨海默病（AD）患者的年龄是否可以预测淀粉样蛋白沉积，病理性tau和神经变性（ATN）方案的生物标志物发现，并调节ATN生物标志物与认知之间的关联。方法：对2355例AD患者进行[11C]匹兹堡化合物B正电子发射断层扫描（PET）、florzolotau (18F) PET、[18F]氟脱氧葡萄糖PET、t1加权磁共振成像和认知能力评估（N = 190/63/252/687/2198）。我们评估了年龄的直接和缓和作用。结果：年轻AD患者Tau负荷和低代谢更为严重。老年患者内侧颞叶（MTL）灰质体积减少程度更大。不同成像方式之间或单一成像方式与认知之间的关系不受年龄的影响。讨论：与年轻患者更严重的tau负担和低代谢相比，老年患者MTL萎缩更为明显。病理标志物与神经退行性变标志物之间的关系与年龄无关。重点：淀粉样蛋白负荷作为病理负担的生物标志物与首次访问记忆诊所的年龄无关。年轻阿尔茨海默病（AD）患者的Tau负荷较高，葡萄糖代谢较低。相比之下，内侧颞叶萎缩在年轻AD患者中较轻。与年龄相适应的标准数据相比，年轻的AD患者表现出更严重的记忆缺陷。年龄对不同影像变量之间或单一影像变量与认知之间的关系没有调节作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Medicine-Psychiatry and Mental Health

CiteScore

7.80

自引率

7.50%

发文量

101

审稿时长

8 weeks

期刊介绍： Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.